Spironolactone

Pharmacologic Category

Antihypertensive; Diuretic, Potassium Sparing; Mineralocorticoid (Aldosterone) Receptor Antagonists

Dosing: Adult

Note: Suspension is not therapeutically equivalent to tablets. Suspension results in 15% to 37% higher serum concentration compared to tablets. Doses of suspension >100 mg may result in higher than expected serum concentrations. In patients requiring >100 mg/dose, use tablets only.

Acne vulgaris, females (alternative agent) (off-label use):

Tablet: Oral: Initial: 25 to 50 mg/day in 1 to 2 divided doses; titrate as needed based on response and tolerability to a usual effective dose of 50 to 100 mg/day in 1 to 2 divided doses; maximum dose: 200 mg/day (AAD [Zaenglein 2016]; Goodfellow 1984; Graber 2019; Muhlemann 1986; Shaw 2000; Yemisci 2005).

Ascites due to cirrhosis:

Note: Generally used in combination with furosemide, but may be used as monotherapy for patients with hypokalemia. For combination therapy, a dosing ratio of spironolactone 100 mg to furosemide 40 mg should generally be maintained, but can be adjusted for electrolyte abnormalities (AASLD [Runyon 2013]; Runyon 2020).

Tablet: Oral: Initial: 100 mg once daily; titrate every 3 to 5 days based on response and tolerability; usual maximum dose: 400 mg once daily (AASLD [Runyon 2013]; Runyon 2020). For small-volume ascites in patients who weigh ≤50 kg, some experts recommend a starting dose of 50 mg once daily (Runyon 2020).

Heart failure:

Note: When initiating therapy, verify the following: serum creatinine ≤2.5 mg/dL in men and ≤2 mg/dL in women or eGFR >30 mL/minute/1.73 m² and serum potassium <5 mEq/L. If patient develops hyperkalemia (serum potassium >5.5 mEq/L), reduce the dose, change to every-other-day dosing, or discontinue therapy. If renal function worsens, consider dose reduction or discontinuation (ACC/AHA/HFSA [Yancy 2017]; ACCF/AHA [Yancy 2013]).

Heart failure with preserved ejection fraction (off-label use):

Note: May be considered for use in patients with symptomatic heart failure with preserved ejection fraction (≥45%) who have an elevated serum natriuretic peptide level or have been hospitalized for heart failure in the last 12 months (ACC/AHA/HFSA [Yancy 2017]; Pitt 2014). Some experts recommend initiating therapy only if serum potassium is ≤4.7 mEq/L and eGFR is ≥30 mL/minute/1.73 m². The same experts recommend dose reduction when serum potassium is >5 mEq/L and discontinuation when serum potassium is >5.5 mEq/L (Borlaug 2020).

Tablet: Oral: Initial: 12.5 mg once daily; may double the dose every 4 weeks if serum potassium remains <5 mEq/L and renal function is stable, up to a maximum target dose of 50 mg/day in 1 or 2 divided doses (ACC/AHA/HFSA [Yancy 2017]; Borlaug 2020; Pitt 2014). Some experts recommend up-titrating therapy only if serum potassium is ≤4.5 mEq/L (Borlaug 2020).

Heart failure with reduced ejection fraction:

Note: Should be considered for use in patients with symptomatic (New York Heart Association class II to IV) heart failure with reduced ejection fraction (≤35%) who are already taking optimal doses of other heart failure therapies (ACC/AHA/HFSA [Yancy 2017]; ACCF/AHA [Yancy 2013]).

Tablet: Oral: Initial: 12.5 to 25 mg once daily; may double the dose every 4 weeks if serum potassium remains <5 mEq/L and renal function is stable, up to a maximum target dose of 50 mg/day in 1 to 2 divided doses (ACC/AHA/HFSA [Yancy 2017]; ACCF/AHA [Yancy 2013]; Pitt 1999).

Suspension: Oral: Initial: 10 to 20 mg once daily. Consider a starting dose of 10 mg once daily in patients at increased risk of hyperkalemia. May titrate to 37.5 mg once daily if serum potassium remains <5 mEq/L and renal function is stable (ACCF/AHA [Yancy 2013]; Colucci 2019; manufacturer labeling).

Post-myocardial infarction, complicated by reduced ejection fraction (off-label use):

Note: Should be considered for use following acute myocardial infarction (MI) in patients with left ventricular ejection fraction ≤40% plus symptoms of heart failure or diabetes. Use in addition to other pharmacologic therapies post MI (ACCF/AHA [O’Gara 2013]; ACCF/AHA [Yancy 2013]).

Tablet: Oral: Initial: 12.5 to 25 mg once daily; may double the dose every 4 weeks if serum potassium remains <5 mEq/L and renal function is stable, up to a maximum target dose of 50 mg/day in 1 to 2 divided doses (ACCF/AHA [Yancy 2013]).

Suspension: Oral: Initial: 10 to 20 mg once daily. Consider a starting dose of 10 mg once daily in patients at increased risk of hyperkalemia. May titrate to 37.5 mg once daily if serum potassium remains <5 mEq/L and renal function is stable (ACCF/AHA [Yancy 2013]; Colucci 2019).

Hirsutism, females (alternative agent) (off-label use):

Note: Typically given in addition to oral contraceptives (OCs) if inadequate response to OCs is observed after 6 months. May be considered as initial therapy for females who cannot conceive or who are using reliable contraception (Barbieri 2019; ES [Martin 2018]).

Tablet: Oral: Initial: 50 mg twice daily; may increase to 100 mg twice daily as needed. Assess response at 6-month intervals before adjusting dose, adding additional agents, or switching to alternative therapy (Barbieri 2019; ES [Martin 2018]).

Hormone therapy for transgender females, male-to-female (adjunctive agent) (off-label use):

Tablet: Oral: Initial: 25 mg once or twice daily in combination with other appropriate agents. Increase at 1-week intervals based on response and tolerability to a usual dose of 100 to 300 mg/day in 2 divided doses; maximum dose: 400 mg/day. Adjust dose with a goal of suppressing serum testosterone levels into the normal range for females (<50 ng/dL) (Deutsch 2016; ES [Hembree 2017]; Prior 1989).

Hypertension (alternative agent):

Note: Not recommended for initial management but may be considered as additional therapy for resistant hypertension in patients who do not respond adequately to combination therapy with preferred agents (ACC/AHA [Whelton 2018]; Bazoukis 2018).

Tablet: Oral: Initial: 25 mg once daily; titrate as needed based on response and tolerability up to 100 mg once daily (ACC/AHA [Whelton 2018]; Bazoukis 2018; Oxlund 2013; Williams 2015). Some experts recommend a starting dose of 12.5 mg once daily and generally do not exceed 50 mg once daily in the absence of primary aldosteronism (Calhoun 2019).

Suspension: Oral: Initial: 20 to 75 mg/day in 1 or 2 divided doses; may titrate at 2-week intervals as needed based on response and tolerability.

Primary aldosteronism:

Tablet: Oral: Initial: 12.5 to 25 mg once daily (ES [Funder 2016]); gradually titrate to the lowest effective dose; usual maximum dose: 400 mg/day (Young 2019). For surgical candidates, the last dose should be administered the day of surgery; discontinue spironolactone on postoperative day 1 (ES [Funder 2016]; Young 2019).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Heart failure: Oral: Avoid use of tablets >25 mg/day (or equivalent dose of suspension) (ACCF/AHA [Yancy 2013]).

Dosing: Renal Impairment: Adult

Tablet:

Ascites due to cirrhosis; hypertension; primary aldosteronism: There are no specific dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.

Heart failure:

eGFR >50 mL/minute/1.73 m²: No initial dosage adjustment necessary.

eGFR 30 to 50 mL/minute/1.73 m²: Initial: 12.5 mg once daily or every other day; may double the dose every 4 weeks if serum potassium remains <5 mEq/L and renal function is stable, up to a maximum target dose of 25 mg/day (ACCF/AHA [Yancy 2013]).

eGFR <30 mL/minute/1.73 m²: Not recommended (ACCF/AHA [Yancy 2013]).

Suspension:

Ascites due to cirrhosis; hypertension: There are no dosage adjustments provided in the manufacturer's labeling.

Heart failure:

eGFR >50 mL/minute/1.73 m²: No initial dosage adjustment necessary.

eGFR 30 to 50 mL/minute/1.73 m²: Initial: 10 mg once daily.

eGFR <30 mL/minute/1.73 m²: Not recommended (ACCF/AHA [Yancy 2013]).

Patients ≥65 years: CrCl <30 mL/minute (regardless of indication): Avoid use due to risk of hyperkalemia (Beers Criteria [AGS 2019]).

Dosing: Hepatic Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling; initiate with low dose and titrate slowly (cirrhosis). Use with caution; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Dosing: Pediatric

Note: Although spironolactone is commercially available in a suspension, it is NOT therapeutically equivalent to the tablets; commercially available suspension results in 15% to 37% higher serum concentration compared to the tablet; pediatric dosing is based on experience with tablets and extemporaneously compounded suspension. Multiple concentrations of oral suspension exist; use extra precaution and prescribe in mg (not mL).

Bronchopulmonary dysplasia (BPD): Limited data available; efficacy results variable. Although the benefits of diuretic therapy in the management of BPD are variable (eg, optimal duration of therapy, impact on pulmonary endpoints), diuretics continue to be used in clinical practice (Slaughter 2013). Infants: Oral: 1.5 mg/kg/dose every 12 hours (Albersheim 1989; Engelhardt 1989; Hoffman 2000; Stewart 2011).

Edema (diuresis): Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 to 3 mg/kg/day divided every 6 to 24 hours; titrate as needed; reported maximum daily dose range: 4 to 6 mg/kg/day in divided doses every 6 to 12 hours or 400 mg/day, whichever is less (Giefer 2011; Kliegman 2016; Sabri 2003; van der Vorst 2006)

Hypertension: Limited data available: Infants, Children, and Adolescents: Oral: Initial: 1 mg/kg/day divided every 12 to 24 hours; titrate as needed up to a maximum daily dose: 3.3 mg/kg/day or 100 mg/day, whichever is less (NHBPEP 2004; Park 2014)

Primary aldosteronism (caused by adrenal hyperplasia), treatment: Limited data available: Infants, Children, and Adolescents: Oral: 1 to 3 mg/kg/day; maximum daily dose: 100 mg/day (Kliegman 2016)

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; spironolactone is substantially excreted by the kidney; use with caution; monitor serum potassium closely. The following recommendations have been suggested: In pediatric patients with mild to moderate failure, consider extended dosing interval (eg, every 12 to 24 hours) and avoid use in severe renal impairment (van der Vorst 2006).

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Calculations

• Glomerular Filtration Rate by Abbreviated MDRD
• Glomerular Filtration Rate by Abbreviated MDRD (SI units)
• Glomerular Filtration Rate by MDRD
• Glomerular Filtration Rate by MDRD (IDMS-Traceable SCr)
• Glomerular Filtration Rate by MDRD (SI units)
• Glomerular Filtration Rate by Schwartz
• Glomerular Filtration Rate Estimate in African Americans by AASK Equation

Use: Labeled Indications

Ascites due to cirrhosis: Management of edema in cirrhosis of the liver unresponsive to fluid and sodium restriction.

Heart failure with reduced ejection fraction: To increase survival, manage edema, and reduce need for hospitalization in patients with heart failure with reduced ejection fraction and New York Heart Association class III to IV symptoms; usually administered in conjunction with other heart failure therapies.

Hypertension: Management of hypertension unresponsive to other therapies.

Primary hyperaldosteronism (tablet only): Short-term preoperative treatment of primary hyperaldosteronism; long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery; long-term maintenance therapy for bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Acne vulgaris, femalesLevel of Evidence [C, G]

Data from a limited number of patients in a small number of randomized, placebo-controlled trials suggest that spironolactone may be beneficial in the treatment of moderate to severe acne in women ^Ref.

Based on the American Academy of Dermatology guidelines of care for the management of acne vulgaris, spironolactone may be beneficial as therapy for the treatment of acne in select females. Access Full Off-Label Monograph

Heart failure with preserved ejection fractionLevel of Evidence [B, G]

Data from a randomized, double-blind, placebo-controlled trial of patients with heart failure with preserved ejection fraction (HFpEF) suggest that spironolactone may be effective at reducing hospitalizations for heart failure, which was one component of the composite primary end point. A subgroup of patients who were enrolled on the basis of natriuretic peptide criteria displayed a reduction in the composite primary end point (cardiovascular death, aborted cardiac arrest, or hospitalization for heart failure) ^Ref.

Based on the American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Failure Society of America update of the guideline for the management of heart failure, spironolactone may be effective and might be considered to reduce hospitalizations for heart failure in appropriately selected patients with symptomatic HFpEF (ejection fraction ≥45%) who have elevated serum natriuretic peptide level or have been hospitalized for HF in the last 12 months.

Heart failure with reduced ejection fraction (New York Heart Association class II)Level of Evidence [G]

Based on the American College of Cardiology Foundation (ACCF)/AHA guideline for the management of heart failure, spironolactone (along with other guideline-directed medical therapies) is effective and recommended to reduce morbidity and mortality in patients with heart failure (New York Heart Association class II to IV) with a left ventricular ejection fraction (LVEF) ≤35%.

Hirsutism, femalesLevel of Evidence [B, G]

Data from a systematic review and network meta-analysis of published randomized trials of adult females with hirsutism (including idiopathic hirsutism and hirsutism in women with polycystic ovary syndrome or nonclassic congenital adrenal hyperplasia) support the use of spironolactone in the treatment of hirsutism ^Ref.

Based on the Endocrine Society clinical practice guideline on the evaluation and treatment of hirsutism in premenopausal women, spironolactone is effective and may be considered among other antiandrogens in the management of this condition. Spironolactone may be considered for initial therapy, either as monotherapy in women who are not at risk for becoming pregnant or in combination with an oral contraceptive in select women with severe hirsutism causing distress and/or a prior history of inadequate response to oral contraceptive therapy. Spironolactone may also be considered for add-on therapy in women who fail to achieve a satisfactory response to initial oral contraceptive monotherapy ^Ref.

Hormone therapy for transgender females, male-to-femaleLevel of Evidence [G]

Based on the Endocrine Society clinical practice guideline for endocrine treatment of gender dysphoric/gender incongruent persons, spironolactone is effective when used in combination with estrogen to block androgens in transgender females, thereby reducing testosterone levels into the normal range for females. The result is decreased hair growth, muscle mass, sexual desire, sperm production, spontaneous erections, and testicular volume, as well as breast growth, male sexual dysfunction, redistribution of body fat, and skin and voice changes ^Ref.

Post myocardial infarction, complicated by reduced ejection fractionLevel of Evidence [G]

According to the ACCF/AHA guideline for the management of ST-elevation myocardial infarction and the AHA/ACC guideline for the management of non–ST-elevation acute coronary syndromes, an aldosterone antagonist should be given to post-myocardial infarction patients (without significant renal dysfunction) who are already on an angiotensin-converting enzyme inhibitor and beta-blocker, who have an LVEF ≤40%, and either symptomatic heart failure or diabetes mellitus.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Acne:

American Academy of Dermatology, "Guidelines of care for the management of acne vulgaris," May 2016

Ascites:

AASLD Practice Guidelines: “Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012,” 2012

Heart Failure:

ACC/AHA, “2013 ACC/AHA Guideline for the Management of Heart Failure,” June 2013

ACC/AHA/HFSA, “2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure,” May 2016

ACC/AHA/HFSA, “2017 Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure,” April 2017

Canadian Cardiovascular Society, “2012 Heart Failure Management Guidelines Update: Focus on Acute and Chronic Heart Failure,” 2012

“HFSA 2010 Comprehensive Heart Failure Practice Guideline,” July 2010

Hirsutism:

Endocrine Society, “Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline,” March 2018

Hormone Therapy for Transgender Females:

Endocrine Society, “Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline,” December 2017

The World Professional Association for Transgender Health, “Standards of care for the health of transsexual, transgender and gender nonconforming people, Version 7,” 2011

Hypertension:

"2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults," November 2017.

"ACC/AHA Expert Consensus Document on Hypertension in the Elderly," 2011

AHA/ACC/CDC, “AHA/ACC/CDC Science Advisory: An Effective Approach to High Blood Pressure Control” November 2013

ASH/ISH “Clinical Practice Guidelines for the Management of Hypertension in the Community: A Statement by the American Society of Hypertension and the International Society of Hypertension,” January 2014

Eighth Joint National Committee (JNC 8), "2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults," December 2013

“National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents,” May 2005

Ischemic Heart Disease:

AHA/ACC, "2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes,” September 2014.

ACC/AHA, “2013 ACC/AHA Guideline for the Management of ST-Elevation Myocardial Infarction,” December 2012

Prevention:

“AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and Other Atherosclerotic Vascular Disease: 2011 Update,” November 2011

Primary Aldosteronsim:

Endocrine Society, “The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment,” March 2016

Administration: Oral

Tablet: Administer with or without food; however, administer consistently with respect to food.

Suspension: Shake well before administering dose. Administer with or without food; however, administer consistently with respect to food.

Administration: Pediatric

Oral: May be taken with or without food; however, consistent administration with or without food is preferred to minimize fluctuations in drug exposure.

Dietary Considerations

Administration with food increases the bioavailability of spironolactone. Excessive potassium intake (eg, salt substitutes, low-salt foods, bananas, nuts) should be avoided.

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 2]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).

Storage/Stability

Tablet: Store below 25°C (77°F).

Suspension: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

Extemporaneously Prepared

5 mg/mL Oral Suspension (ASHP Standard Concentration) (ASHP 2017)

A 5 mg/mL oral suspension may be made with tablets. Crush twelve 50 mg tablets in a mortar and reduce to a fine powder. Add small portions of distilled water and mix to a uniform paste; mix while adding cherry syrup to almost 120 mL; transfer to a calibrated glass bottle, rinse mortar with cherry syrup, and add quantity of cherry syrup sufficient to make 120 mL. Label "shake well" and "refrigerate." Stable for 28 days at room temperature or refrigerated (Mathur 1989).

Mathur LK, Wickman A. Stability of extemporaneously compounded spironolactone suspensions. Am J Hosp Pharm. 1989;46(10):2040-2042.[PubMed 2816959]

1 mg/mL Oral Suspension

A 1 mg/mL oral suspension may be made with tablets. Crush ten 25 mg tablets in a mortar and reduce to a fine powder. Add a small amount of purified water and soak for 5 minutes; add 50 mL 1.5% carboxymethylcellulose, 100 mL syrup NF, and mix to a uniform paste; mix while adding purified water in incremental proportions to almost 250 mL; transfer to a calibrated bottle, rinse mortar with purified water, and add quantity of purified water sufficient to make 250 mL. Label "shake well." Stable for 3 months at room temperature or refrigerated (Nahata 1993).

Nahata MC, Morosco RS, and Hipple TF, "Stability of Spironolactone in an Extemporaneously Prepared Suspension at Two Temperatures," Ann Pharmacother. 1993, 27(10):1198-9.[PubMed 8251687]

25 mg/mL Oral Suspension

A 25 mg/mL oral suspension may be made with tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus. Crush one-hundred-twenty 25 mg tablets in a mortar and reduce to a fine powder. Add small portions of chosen vehicle and mix to a uniform paste; mix while adding vehicle in incremental proportions to almost 120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Store in amber bottles; label "shake well" and "refrigerate." Stable for 60 days refrigerated (Allen 1996).

Allen LV Jr and Erickson MA 3rd, "Stability of Ketoconazole, Metolazone, Metronidazole, Procainamide Hydrochloride, and Spironolactone in Extemporaneously Compounded Oral Liquids," Am J Health Syst Pharm. 1996, 53(17):2073-8.[PubMed 8870895]

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to get rid of extra fluid.

• It is used to raise potassium stores in the body.

• It is used to treat heart failure (weak heart).

• It is used to treat high blood pressure.

• It is used to treat some people with high aldosterone levels.

• It is used to treat some kidney problems.

• It may be given to you for other reasons. Talk with the doctor.

Frequently reported side effects of this drug

• Diarrhea

• Fatigue

• Headache

• Hair loss

• Nausea

• Vomiting

• Abdominal cramps

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Fluid and electrolyte problems like mood changes, confusion, muscle pain or weakness, abnormal heartbeat, dizziness, passing out, fast heartbeat, increased thirst, seizures, loss of strength and energy, lack of appetite, unable to pass urine or change in amount of urine passed, dry mouth, dry eyes, nausea, or vomiting.

• Kidney problems like unable to pass urine, blood in the urine, change in amount of urine passed, or weight gain.

• Stevens-Johnson syndrome/toxic epidermal necrolysis like red, swollen, blistered, or peeling skin (with or without fever); red or irritated eyes; or sores in mouth, throat, nose, or eyes.

• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin.

• Bleeding like vomiting blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine; black, red, or tarry stools; bleeding from the gums; abnormal vaginal bleeding; bruises without a reason or that get bigger; or any severe bleeding or persistent bleeding.

• Severe dizziness

• Passing out

• Confusion

• Change in balance

• Decreased sex drive

• Sexual dysfunction

• Chills

• Sore throat

• Menstrual changes

• Breast pain

• Enlarged breasts (males)

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

Geriatric Patients: High-Risk Medication:

International issues:

Contraindications

Hyperkalemia; Addison disease; concomitant use with eplerenone.

Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to spironolactone or any component of the formulation; acute renal insufficiency; severe renal impairment (eGFR <30 mL/minute/1.73 m²); anuria; concomitant use with heparin or low molecular weight heparin; pregnancy; breastfeeding.

Warnings/Precautions

Concerns related to adverse effects:

• Fluid/electrolyte imbalance: Fluid and electrolyte imbalance (eg, hypomagnesemia, hyponatremia, hypocalcemia, hyperglycemia, hyperkalemia) may occur. Patients with heart failure, renal disease, or cirrhosis may be particularly susceptible. Monitor and correct electrolyte disturbances; adjust dose to avoid dehydration.

• Gout: Asymptomatic hyperuricemia may occur and gout may be precipitated (rare).

• Gynecomastia: May occur; risk increases based on dose and onset is variable (after 1 to 2 months to over a year of therapy); usually reversible following discontinuation of therapy.

• Hyperkalemia: Hyperkalemia may occur; risk of hyperkalemia is increased with renal impairment, excessive potassium intake, and patients taking certain drugs (eg, angiotensin-converting enzyme [ACE] inhibitors, angiotensin-receptor blockers [ARBs], nonsteroidal anti-inflammatory drugs). Monitor serum potassium closely. The concurrent use of larger doses of ACE inhibitors (eg, lisinopril ≥10 mg daily in adults) also increases the risk of hyperkalemia (ACC/AHA [Yancy 2013]). Dose reduction or interruption of therapy may be necessary with development of hyperkalemia. Use is contraindicated in patients with hyperkalemia; use caution in conditions known to cause hyperkalemia.

• Tumorigenic: Shown to be a tumorigen in chronic toxicity animal studies. Avoid unnecessary use.

Disease-related concerns:

• Adrenal vein catheterization: Discontinue use prior to adrenal vein catheterization.

• Heart failure: When evaluating a heart failure patient for spironolactone treatment, eGFR should be >30 mL/minute/1.73 m² or creatinine should be ≤2.5 mg/dL (men) or ≤2 mg/dL (women) with no recent worsening and potassium <5 mEq/L with no history of severe hyperkalemia (ACC/AHA [Yancy 2013]). Serum potassium levels require close monitoring and management if elevated. American College of Cardiology/American Heart Association recommends considering discontinuation upon the development of serum potassium >5.5 mEq/L or worsening renal function with careful evaluation of the entire medical regimen. Avoid triple therapy with the combined use of an ACE inhibitor, ARB, and spironolactone. Therapy may need to be modified during an episode of diarrhea or dehydration or when loop diuretic therapy is interrupted (ACC/AHA [Yancy 2013]).

• Hepatic impairment: Use with caution in patients with hepatic impairment; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

• Renal impairment: Risk of hyperkalemia is increased with declining renal function and with the concurrent use of larger doses of ACE inhibitors (eg, lisinopril ≥10 mg daily in adults) (ACC/AHA [Yancy 2013]). Use with caution in patients with renal impairment.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Avoid use of tablets >25 mg/day in elderly patients with heart failure or with reduced renal function (eg, CrCl <30 mL/minute or eGFR ≤30 mL/minute/1.73 m² [ACC/AHA (Yancy 2013)]).

Other warnings/precautions:

• Suspension: Suspension is NOT therapeutically equivalent to tablets. In patients requiring >100 mg/dose, use tablets (>100 mg/dose of suspension may result in spironolactone concentration higher than expected).

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

When used in combination with ACE inhibitors or ARBs, monitor patient for increased risk of hyperkalemia.

Avoid in patients with a CrCl <30 mL/minute.

Warnings: Additional Pediatric Considerations

Due to pharmacologic properties (aldosterone antagonist and some androgen receptor blocking), spironolactone may cause endocrine-related adverse effects including gynecomastia; an ovarian cyst has been reported in a premature neonate following spironolactone use (Vachharajani 2001); long-term effects have not been described in pediatric patients. When used with a thiazide diuretic, may cause hypercalcuria; in neonates, monitor calcium and ensure adequate supplementation with use.

Pregnancy Considerations

Spironolactone crosses the placenta (Regitz-Zagrosek [ESC 2018]).

Based on the mechanism of action and data from animal reproduction studies, in utero exposure to spironolactone may cause feminization of a male fetus (limited human data; Liszewski 2019).

Chronic maternal hypertension is associated with adverse events in the fetus/infant. The risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death may be increased with chronic hypertension in pregnancy. Actual risks may be related to duration and severity of maternal hypertension. The use of mineralocorticoid receptor antagonists for the treatment of hypertension in pregnancy is generally not recommended (ACOG 203 2019).

The treatment of edema associated with chronic heart failure during pregnancy is similar to that of nonpregnant patients. However, the use of mineralocorticoid receptor antagonists is not recommended. Patients diagnosed after delivery can be treated according to heart failure guidelines (ESC [Bauersachs 2016]; ESC [Regitz-Zagrosek 2018]).

Information related to the use of mineralocorticoid receptor antagonists for the treatment of primary hyperaldosteronism in pregnancy is limited. Women who require use of spironolactone for the treatment of primary hyperaldosteronism should use the lowest effective dose prior to a planned pregnancy, then stop treatment during the first trimester once the pregnancy is confirmed. Use of a mineralocorticoid receptor antagonist can be considered again in the second and third trimesters if necessary; high doses have been associated with intrauterine growth restriction (monitor) (Riester 2015).

Use of spironolactone is associated with menstrual irregularities (dose dependent); contraception is recommended when used in premenopausal women for the treatment of conditions such as hirsutism and acne (AAD [Zaenglein 2016]; Endocrine Society [Martin 2018]).

Breast-Feeding Considerations

The active metabolite of spironolactone (canrenone) is present in breast milk.

Information is available from a case report following maternal use of spironolactone 25 mg twice daily throughout pregnancy, then 4 times daily after delivery. Milk and maternal serum samples were obtained 17 days after birth. Two hours after the maternal dose, canrenone concentrations were ~144 ng/mL (serum) and ~104 ng/mL (milk). When measured 14.5 hours after the dose, canrenone concentrations were ~92 ng/mL (serum) and ~47 ng/mL (milk). The authors calculated the estimated maximum amount of canrenone to the breastfeeding infant to be ~0.2% of the maternal dose of spironolactone (Phelps 1977).

Spironolactone is considered compatible with breastfeeding (WHO 2002). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Briggs' Drugs in Pregnancy & Lactation

• Spironolactone

Adverse Reactions

1% to 10%:

Endocrine & metabolic: Gynecomastia (9%)

Frequency not defined.

Cardiovascular: Vasculitis

Central nervous system: Ataxia, confusion, dizziness, drowsiness, headache, lethargy, nipple pain

Dermatologic: Alopecia, chloasma, erythematous maculopapular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria

Endocrine & metabolic: Amenorrhea, asymptomatic hyperuricemia, decreased libido, electrolyte disorder, gout, hyperglycemia, hyperkalemia, hyperuricemia, hypocalcemia, hypomagnesemia, hyponatremia, hypovolemia

Gastrointestinal: Abdominal cramps, diarrhea, gastritis, gastrointestinal hemorrhage, gastrointestinal ulcer, nausea, vomiting

Genitourinary: Erectile dysfunction, irregular menses, mastalgia, postmenopausal bleeding

Hematologic & oncologic: Agranulocytosis, leukopenia, thrombocytopenia

Hepatic: Hepatotoxicity

Hypersensitivity: Anaphylaxis

Immunologic: Drug reaction with eosinophilia and systemic symptoms

Neuromuscular & skeletal: Lower limb cramp

Renal: Renal failure syndrome, renal insufficiency

Miscellaneous: Fever

Postmarketing: Metabolic acidosis (in patients with cirrhosis [Feinfeld 1978; Gabow 1979])

* See Cautions in AHFS Essentials for additional information.

Metabolism/Transport Effects

None known.

Drug Interactions Open Interactions

Abiraterone Acetate: Spironolactone may diminish the therapeutic effect of Abiraterone Acetate. Risk C: Monitor therapy

Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Alpha-/Beta-Agonists: Spironolactone may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Risk C: Monitor therapy

Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered. Risk D: Consider therapy modification

AMILoride: May enhance the hyperkalemic effect of Spironolactone. Risk X: Avoid combination

Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis. Risk D: Consider therapy modification

Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

Angiotensin-Converting Enzyme Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. Risk C: Monitor therapy

Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). Risk C: Monitor therapy

Aspirin: May diminish the therapeutic effect of Spironolactone. Risk C: Monitor therapy

AtorvaSTATin: May enhance the adverse/toxic effect of Spironolactone. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity. Risk C: Monitor therapy

Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents. Risk C: Monitor therapy

Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. Risk X: Avoid combination

Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone. Risk C: Monitor therapy

Cholestyramine Resin: May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination. Risk C: Monitor therapy

Ciprofloxacin (Systemic): Spironolactone may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). Risk C: Monitor therapy

Cosyntropin: Spironolactone may diminish the diagnostic effect of Cosyntropin. Management: Patients receiving spironolactone should omit their pre-test dose on the day selected for cosyntropin testing. Risk D: Consider therapy modification

CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic). Risk X: Avoid combination

Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Risk C: Monitor therapy

Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased. Risk C: Monitor therapy

Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations. Risk C: Monitor therapy

Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Risk C: Monitor therapy

Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension. Risk D: Consider therapy modification

Heparin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated. Risk C: Monitor therapy

Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated. Risk C: Monitor therapy

Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. Risk C: Monitor therapy

Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products. Risk C: Monitor therapy

Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane. Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane. Risk D: Consider therapy modification

Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Neuromuscular-Blocking Agents (Nondepolarizing): Spironolactone may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). Risk C: Monitor therapy

Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nicorandil: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. Risk C: Monitor therapy

Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion. Risk D: Consider therapy modification

Opioid Agonists: May enhance the adverse/toxic effect of Diuretics. Opioid Agonists may diminish the therapeutic effect of Diuretics. Risk C: Monitor therapy

Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. Risk C: Monitor therapy

Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk D: Consider therapy modification

Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Risk C: Monitor therapy

QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine. Risk C: Monitor therapy

Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status. Risk D: Consider therapy modification

Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic). Risk C: Monitor therapy

Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Risk C: Monitor therapy

Triamterene: May enhance the hyperkalemic effect of Spironolactone. Risk X: Avoid combination

Trimethoprim: May enhance the hyperkalemic effect of Spironolactone. Risk C: Monitor therapy

Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents. Risk C: Monitor therapy

Food Interactions

Food increases the bioavailability of unmetabolized spironolactone by ~90% to 95%.

Test Interactions

May interfere with the radioimmunoassay for digoxin; may lead to false negative aldosterone/renin ratio (ARR) (Funder 2016; Mulatero 2002)

Monitoring Parameters

Blood pressure, serum electrolytes (potassium [within 1 week of initiation or dose titration and regularly thereafter], sodium), uric acid, glucose, renal function, volume status

Heart failure: Serum potassium and renal function should be checked in 3 days after initiation, at 1 week after initiation, at least monthly for the first 3 months of therapy, and every 3 months thereafter. If adding or increasing the dose of concomitant ACE inhibitors or ARBs, a new cycle of monitoring should be done. If serum potassium increases to >5.5 mEq/L or renal function worsens, hold doses until potassium is <5 mEq/L and consider restarting with a reduced dose after confirming resolution of hyperkalemia/renal insufficiency for at least 72 hours (ACC/AHA [Yancy 2013]).

Transgender hormone therapy: Serum testosterone levels (goal: <50 ng/dL) every 3 months during the first year and then annually or biannually; serum electrolytes every 3 months for the first year then annually; routine cancer and laboratory screening as in non-transgender individuals for all tissues present (ES [Hembree 2017]).

Advanced Practitioners Physical Assessment/Monitoring

Diuretic effect may be delayed 2 to 3 days. Assess serum electrolytes on a regular basis. Assess fluid status and monitor for CNS changes (drowsiness, headache, confusion), rash, gynecomastia, dehydration, and hyperkalemia during therapy.

Nursing Physical Assessment/Monitoring

Diuretic effect may be delayed 2 to 3 days. Monitor serum electrolytes on a regular basis during therapy. Assess fluid status and monitor for CNS changes (drowsiness, headache, confusion), rash, gynecomastia, and hyperkalemia during therapy.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Suspension, Oral:

CaroSpir: 25 mg/5 mL (118 mL, 473 mL) [contains saccharin sodium; banana flavor]

Tablet, Oral:

Aldactone: 25 mg

Aldactone: 50 mg, 100 mg [scored]

Generic: 25 mg, 50 mg, 100 mg

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Tablet, Oral:

Aldactone: 25 mg, 100 mg

Generic: 25 mg, 100 mg

Anatomic Therapeutic Chemical (ATC) Classification

• C03DA01

Generic Available (US)

May be product dependent

Pricing: US

Suspension (CaroSpir Oral)

25 mg/5 mL (per mL): $3.26

Tablets (Aldactone Oral)

25 mg (per each): $3.05

50 mg (per each): $5.35

100 mg (per each): $8.98

Tablets (Spironolactone Oral)

25 mg (per each): $0.19 - $0.46

50 mg (per each): $0.81 - $0.88

100 mg (per each): $1.42

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well

Pharmacodynamics/Kinetics

Note: Suspension results in 15% to 37% higher serum concentration compared to the tablet; doses of suspension >100 mg may result in higher spironolactone concentrations than expected.

Duration: Tablet: 2 to 3 days

Bioavailability: High-fat/-calorie meal increased the bioavailability of spironolactone ~90%.

Protein binding: >90%

Metabolism: Rapid and extensive; hepatic to multiple metabolites, including active metabolites canrenone, 7-alpha-spirolactone, and 6-beta-hydroxy-7-alpha

Half-life elimination:

Tablet: Spironolactone: 1.4 hours; Canrenone: 16.5 hours (terminal); 7-alpha-spirolactone: 13.8 hours (terminal)

Suspension: Spironolactone: 1 to 2 hours; Canrenone, 7-alpha-spirolactone, and 6-beta-hydroxy-7-alpha: 10 to 35 hours.

Time to peak, serum:

Tablet: 2.6 to 4.3 hours (primarily as active metabolites)

Suspension: Spironolactone: 0.5 to 1.5 hours; Canrenone: 2.5 to 5 hours

Excretion: Urine (primarily as metabolites) and bile (secondary)

Pharmacodynamics/Kinetics: Additional Considerations

Hepatic function impairment: Terminal half-life is increased in patients with cirrhotic ascites.

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Beers Criteria 2019: Potentially Inappropriate Medication Use in Older Adults ≥65 Years of Age
• Safe Handling of Hazardous Drugs

Pharmacotherapy Pearls

Maximum diuretic effect may be delayed 2 to 3 days and maximum antihypertensive effects may be delayed 2 to 3 weeks.

FDA Approval Date

January 21, 1960

References

<800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.

2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767.[PubMed 30693946]

Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr. 1989;115(4):615-620.[PubMed 2677293]

Aldactone (spironolactone) [prescribing information]. New York, NY: Pfizer Inc; April 2018.

Aldactone (spironolactone) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2015.

American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. Obstet Gynecol. 2019;133(1):e26-e50.[PubMed 30575676]

Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in J Am Coll Cardiol. 2014;64(24):2713-2714]. J Am Coll Cardiol. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.[PubMed 25260718]

Aronow WS, Fleg JL, Pepine CJ, et al. ACC/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57(20):2037-2114.[PubMed 21524875]

ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.

Barbieri RL, Chang J. Treatment of hirsutism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 18, 2019.

Barrionuevo P, Nabhan M, Altavar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018;103(4):1258-1264. doi: 10.1210/jc.2017-02052.[PubMed 29522176]

Bauersachs J, Arrigo M, Hilfiker-Kleiner D, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18(9):1096-1105.[PubMed 27338866]

Bazoukis G, Thomopoulos C, Tsioufis C. Effect of mineralocorticoid antagonists on blood pressure lowering: overview and meta-analysis of randomized controlled trials in hypertension. J Hypertens. 2018;36(5):987-994. doi: 10.1097/HJH.0000000000001671.[PubMed 29356711]

Borlaug BA, Colucci WS. Treatment and prognosis of heart failure with preserved ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 7, 2020.

Calhoun DA, Townsend RR. Treatment of resistant hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 18, 2019.

Carospir (spironolactone) [prescribing information]. Farmville, NC: CMP Pharma; August 2017.

Colucci WS. Secondary pharmacologic therapy in heart failure with reduced ejection fraction (HFrEF) in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 26, 2019.

Deutsch MB. Guidelines for the primary and gender-affirming care of transgender and nonbinary people. Center of Excellence for Transgender Health. http://transhealth.ucsf.edu/trans?page=guidelines-home. Published June 17, 2016. Accessed January 14, 2019.

Eichenwald EC, ed. Cloherty and Stark's Manual of Neonatal Care. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2017.

Engelhardt B, Blalock WA, DonLevy S, Rush M, Hazinski TA. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1989;114(4 Pt 1):619-624.[PubMed 2926575]

Fanaroff AA, Fanaroff JM, eds. Klaus & Fanaroff's Care of the High-Risk Neonate. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.

Feinfeld DA, Carvounis CP. Fatal hyperkalemia and hyperchloremic acidosis. Association with spironolactone in the absence of renal impairment. JAMA. 1978;240(14):1516.[PubMed 682358]

Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.[PubMed 26934393]

Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intern Med. 1979;90(3):338-340.[PubMed 426401]

Giefer MJ, Murray KF, Colletti RB. Pathophysiology, diagnosis, and management of pediatric ascites. J Pediatr Gastroenterol Nutr. 2011;52(5):503-513.[PubMed 21464748]

Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. Hypertension.[PubMed 24243703]

Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111(2):209-214. doi: 10.1111/j.1365-2133.1984.tb04045.x.[PubMed 6235834]

Graber E. Hormonal therapy for women with acne vulgaris. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed September 18, 2019.

Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. Endocr Pract. 2017;23(12):1437. doi: 10.4158/1934-2403-23.12.1437.[PubMed 29320642]

Hoffman DJ, Gerdes JS, Abbasi S. Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. J Perinatol. 2000;20(1):41-45.[PubMed 10693099]

James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.[PubMed 24352797]

Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. Nelson Textbook of Pediatrics. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.

Lindenfeld J, Albert NM, Boehmer JP, et al, “HFSA 2010 Comprehensive Heart Failure Practice Guideline,” J Card Fail, 2010, 16(6):e1-194.[PubMed 20610207]

Liszewski W, Boull C. Lack of evidence for feminization of males exposed to spironolactone in utero: a systematic review. J Am Acad Dermatol. 2019;80(4):1147-1148.[PubMed 30352280]

Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(4):1233-1257. doi: 10.1210/jc.2018-00241.[PubMed 29522147]

Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115(2):227-232. doi: 10.1111/j.1365-2133.1986.tb05722.x.[PubMed 2943311]

Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension. 2002;40(6):897-902.[PubMed 12468576]

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, "The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,” Pediatrics, 2004, 114(2 Suppl 4th Report):555-76.[PubMed 15286277]

O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013;128(25):e481]. Circulation. 2013;127(4):e362-e425.[PubMed 23247304]

Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31(10):2094-2102. doi: 10.1097/HJH.0b013e3283638b1a.[PubMed 24107738]

Park, MK. Park's Pediatric Cardiology for Practitioners. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.

Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk. J Pharm Sci. 1977;66(8):1203.[PubMed 894512]

Pitt B, Pfeffer MA, Assmann SF, et al; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. doi: 10.1056/NEJMoa1313731.[PubMed 24716680]

Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709-717. doi: 10.1056/NEJM199909023411001.[PubMed 10471456]

Prior JC, Vigna YM, Watson D. Spironolactone with physiological female steroids for presurgical therapy of male-to-female transsexualism. Arch Sex Behav. 1989;18(1):49-57. doi: 10.1007/bf01579291.[PubMed 2540730]

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241.[PubMed 30165544[]

Riester A, Reincke M. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy. Eur J Endocrinol. 2015;172(1):R23-R30.[PubMed 25163723]

Runyon BA. Ascites in adults with cirrhosis: Initial therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed February 7, 2020.

Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases practice guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology. 2013;57(4):1651-1653. doi: 10.1002/hep.26359.[PubMed 23463403]

Sabri M, Saps M, Peters JM. Pathophysiology and management of pediatric ascites. Curr Gastroenterol Rep. 2003;5(3):240-246.[PubMed 12734047]

Shaw JC. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol. 2000;43(3):498-502. doi: 10.1067/mjd.2000.105557.[PubMed 10954662]

Slaughter JL, Stenger MR, Reagan PB. Variation in the use of diuretic therapy for infants with bronchopulmonary dysplasia. Pediatrics. 2013;131(4):716-723.[PubMed 23478874]

Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACC Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” Circulation, 2011, 124(22):2458-73.[PubMed 22052934]

Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;(9):CD001817.[PubMed 21901679]

US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf. Updated September 2016. Accessed October 5, 2016.

Vachharajani AJ, Shah JK, Paes BA. Ovarian cyst in a premature infant treated with spironolactone. Am J Perinatol. 2001;18(6):353-356.[PubMed 11607853]

van der Vorst MM, Kist JE, van der Heijden AJ, Burggraaf J. Diuretics in pediatrics: current knowledge and future prospects. Paediatr Drugs. 2006;8(4):245-264.[PubMed 16898855]

Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014;16(1):14-26. doi: 10.1111/jch.12237.[PubMed 24341872]

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018;71(6):e140-e144]. Hypertension. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065.[PubMed 29133356]

Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3.[PubMed 26414968]

World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/

Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509.[PubMed 28455343]

Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-e327. doi: 10.1161/CIR.0b013e31829e8776.[PubMed 23741058]

Yemisci A, Gorgulu A, Piskin S. Effects and side-effects of spironolactone therapy in women with acne. J Eur Acad Dermatol Venereol. 2005;19(2):163-166. doi: 10.1111/j.1468-3083.2005.01072.x.[PubMed 15752283]

Young WF Jr. Treatment of primary aldosteronism. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed November 22, 2019.

Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. doi: 10.1016/j.jaad.2015.12.037[PubMed 26897386]

Brand Names: International

Aldactin (TW); Aldacton (TR); Aldactone (AE, AT, AU, BB, BD, BE, BF, BH, BJ, BR, CH, CI, CO, CY, CZ, DE, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NO, OM, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TW, TZ, UG, VE, YE, ZA, ZM, ZW); Aldactone A (AR, BM, BS, BZ, CR, DO, EC, GT, GY, HN, JM, NI, PA, SR, SV, TT, UY); Aldoxol (PY); Alizar (CL); Alspiron (RO); Altone (TH); Antagerone (EG); Belactone (LK); Diulactone (PH, VN); Epilactone (EG); Flumach (FR); Huma-Spiroton (HU); Hyles (TH); Indurit (PY); Lactone (PH); Letonal (ID); Noractone (AE, JO); Osiren (AT); Osyrol (DE, JP); Pondactone (TH); S-Tone (TH); Skyton (TW); Spectone (EG); Spilac (LK); Spinolac (VN); Spiractin (AU, ZA); Spiretic (BD); Spirix (DK, FI, NO); Spiroctan (FR, LU); Spirofar (PH); Spirola (ID); Spirolacton (ID); Spirolon (BF, BJ, CI, EC, ET, GH, GM, GN, KE, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW); Spiron (DK, HU); Spirone (PE); Spirono-Isis (DE); Spironolacton-ratiopharm (LU); Spironolactone-Eurogenerics (LU); Spironolactone-Searle (LU); Spiros (PH); Spirotone (NZ, TW); Unilactone (AE, BH, CY, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE); Uractone (LU); Uractonum (SG, TR); Verospiron (BD, BG, CZ, EE, HU, LT, SK, UA); Vivitar (CR, DO, GT, HN, MX, NI, PA, SV)

Last Updated 2/20/20